A Rare Case of Primary Vulvar Diffuse Large B‐Cell Lymphoma: A Case Report Authors: M Singh, S Ngakhusi, A Shrestha, P Subedi, K Khadka, H P Dhakal Published: 2024 ABSTRACT ABSTRACTPrimary vulvar diffuse large B‐cell lymphoma is a diagnostically challenging malignant tumor due to its low incidence and diverse clinical presentations. It has a good prognosis and is usually radio‐chemotherapy‐responsive. This case report emphasizes considering lymphoma as a differential in vulvar inflammatory conditions.Keywords: B‐cell lymphoma, lymphoid, non‐Hodgkin's lymphoma, vulva Introduction Non‐Hodgkin's lymphomas (NHL) comprises 70%–80% of all lymphoma cases [1]. They are generally found in lymph nodes or other lymphoid tissue like the spleen and bone marrow [2]. However, around 20%–24% of NHL cases are extranodal and mostly originate from areas like the gastrointestinal tract, lungs, central nervous system, skin, thyroid, and salivary glands. Although the secondary involvement of the female genital tract, especially the ovaries is common, primary genital tract lymphomas are exceptionally rare, accounting for less than 0.5% of genital cancers and 1.5% of all NHL cases. These tumors are anatomically reported in the following order of prevalence: ovary (49%), uterus (29%), fallopian tube (11%), vagina (7%), and vulva (4%) [2, 3]. Diffuse large B cell lymphoma (DLBCL) is a subtype of non‐Hodgkin lymphoma that comprises around 30% of total NHL cases. DLBCL can be further classified into three subtypes; germinal center B‐cell (GCBC), activated B‐cell (ABC), and unclassified subtype [1]. So far only 13 DLBCL of vulva are reported in the medical literature [4]. We present a rare case of DLBCL of the vulva in a 78‐year‐old elderly patient. Case History/Examination A 78‐year‐old postmenopausal patient presented with a history of a painless small, hard mass on labia majora since 1 year back. The patient also complained of occasional burning micturition but no history of per vaginal (PV) bleeding or discharge. Past medical history is significant for Hypothyroidism. She is Gravida 6 and para 4 with 2 histories of spontaneous abortion. Menopause happened at the age of 42 years old. There is no history of weight loss and fever. Family history is insignificant. Abdominal examination revealed normal findings. On external examination, a huge, solid, whorl, ulcerative periurethral mass measuring 5 × 6cm was noted. PV examination revealed the mass originated from the periurethral area. Per speculum examination revealed a healthy cervix, and no abnormal discharge. Differential Diagnosis, Investigations and Treatment Transvaginal sonography revealed a well‐defined mass lesion of homogeneous echogenicity measuring 6.0 × 4.0 cm in the anterior vaginal wall completely filling the vaginal lumen with increased intrinsic vascularity. Biopsy of the mass was diagnosed as chronic nonspecific inflammation. Later, magnetic resonance and imaging (MRI) of the pelvis revealed a well‐defined, solid, encapsulated, smooth outlined lesion measuring 7.0 × 5.1 × 4.8 cm in size in the perineal region located inferior to the pubic symphysis, and extending cranially in between the urethra anteriorly and vagina posteriorly. The lesion was seen extending up to the bladder neck and anterior vaginal fornix level superiorly and extending up to the introitus inferiorly. Posteriorly, it was seen abutting the anal canal with a distinct fat plane in between and displacing the bulb of the vestibule and crura of the clitoris. The vaginal lumen is compressed posteriorly by the lesion. Cystoscopy revealed a periurethral mass, with external compression at distal 1 cm of the urethra. Her laboratory findings showed an increased level of Lactate Dehydrogenase level of 219 U/L (reference range: 100–210). Peripheral blood smear was within normal limits. Multi‐detector Computed Tomography of the neck and chest revealed bilateral sub‐centimeter cervical lymph nodes and prominent mediastinal lymph nodes in the paratracheal, pre‐carinal, AP window, and pre‐vascular; the largest measuring 1.6 × 1.7 cm in the pre‐carinal region. Bone marrow aspiration and biopsy revealed no involvement with atypical lymphoid cells. Subsequently, a vulvar punch biopsy was taken. On histomorphological examination, infiltration by discohesive sheets of atypical lymphoid cells in the subepithelial stroma was seen. These atypical lymphoid cells exhibited pleomorphism with a high nucleo‐cytoplasmic ratio, large nucleus, irregular nuclear contours, conspicuous nucleoli, and scant cytoplasm. Mitosis noted. Fibrinoid necrosis of vessels was also seen (Figure 1). Hematoxylin and eosin‐stained section show discohesive sheets of atypical lymphoid cells have large nucleus, irregular nuclear contours, conspicuous nucleoli, and scant cytoplasm. Mitosis noted. (400×). Immunohistochemistry (IHC) analysis, showed tumor cells positive for CD20, BCL6, MUM1, CMYC, and BCL2 and negative for CK, CD3, CD10, SOX11, and Ki67 70%. (Figure 2a–c) The overall histomorphological features combined with the immunohistochemical analysis profile favored the diagnosis of diffuse large B‐cell lymphoma, active B‐cell immunophenotype of the vulva. (a) IHC shows tumor cells are positive for BCL2. (b) IHC shows tumor cells are positive for CD20. (c) IHC shows tumor cells are negative for Ki67. Subsequently, an R‐CVP chemotherapy cycle was initiated which included Inj. Rituximab 500 mg on Day 1, Inj. Vincristine sulphate 2 mg on Day 2, Inj. Cyclophosphamide 1000 mg on Day 2 and tablet prednisolone 60 mg for Day 1–5. Conclusion and Results (Outcome and Follow‐Up) Upon completion of 6 cycles of chemotherapy, a positron emission tomography‐computed tomography scan of the whole body with contrast was done after 2.5 months which revealed ill‐defined soft tissue thickening of the vulva/lower vagina with minimal f‐18 fluorodeoxyglucose uptake (Deauville score 2), likely treated disease. This case report aims to highlight the occurrence of exceptionally rare primary NHL of the vulva as it can be misdiagnosed as an inflammatory condition. It is important to perform IHC whenever diffuse sheets of lymphoid cells are identified in any biopsy. Discussion Based on one of the recent studies, primary vulvar DLBCL is bi‐modally distributed between the age group of 25–43 and 62–79 with a mean age of 58. Our patient is a 78‐year‐old elderly woman. Clinically, the patient with vulvar DLBCL may present with complaints of tender to non‐tender mass with or without ulceration. Erythema, edema, and pruritus may also be present [5]. Our patient presented with the complaint of a hard nodule in the right labia majora, which appeared to be an ulcerative peri‐urethral mass on examination. Since there are only a few reported cases of primary vulvar DLBCL in medical literature, it is diagnostically challenging. The differential diagnosis for vulvar DLBCL ranges from inflammatory lymphoid conditions (lichenoid dermatoses, extramedullary myeloid cell tumor, Langerhans cell granulomatosis) to carcinomas (Neuroendocrine carcinomas like Merkel cell or metastatic, lymphoepithelioma‐like, poorly differentiated squamous cell, Bartholin's gland adenocarcinoma) and other conditions like melanoma, rhabdomyosarcoma, extraosseous Ewing's sarcoma/primitive neuroectodermal tumor, lipoma, and Bartholin gland cyst or abscess [6]. Pelvic MRI emerges as the most effective imaging tool for this purpose [7, 8]. From a morphological perspective, DLBCL is characterized by a diffuse proliferation of neoplastic large B lymphoid cells. These cells have nuclei that are equal to or larger than the typical nuclei of macrophages, and they may feature prominent central nucleoli, and smaller nucleoli, or show clear signs of anaplasia [4]. Based on the cell of origin, gene expression profiling has shown two primary subtypes of DLBCL: GCBC type and ABC type. The GCBC type originates from post‐germinal center B cells, while the ABC type is believed to arise from B cells after the germinal center phase. ABC‐DLBCL, associated with the heightened activity of nuclear factor‐kB (NF‐kB), tends to be more aggressive and has a poorer prognosis. Our patient has ABC‐type DLBCL [9, 10, 11, 12]. In cases of DLBCL, the typical IHC analysis findings involve large, atypical lymphocytes that are negative for CD3 but positive for CD20, exhibiting a Ki‐67 labeling index surpassing 80%. To determine the cell of origin, staining for CD10, Bcl‐6, and MUM‐1 is conducted using the Hans algorithm [13]. Confirmation of the double‐expression phenotype involves staining for Bcl‐2 and c‐myc [14]. Additionally, Epstein–Barr virus in situ hybridization staining assists in identifying EBV‐positive DLBCL. In some instances, DLBCL may be suspected despite negative findings for CD3 and CD20 in H&E staining. In such scenarios, it is important to entertain the likelihood of a poorly differentiated carcinoma or a small round‐cell tumor as part of the standard diagnostic process. Nevertheless, the spectrum of potential diagnoses broadens to include CD20‐negative DLBCL and anaplastic large‐cell lymphoma when lymphoma is under consideration [15]. In our case, immunohistochemistry analysis revealed the tumor cells were positive for CD20, BCL6, MUM1, CMYC, and BCL2 and negative for CK, CD3, CD10, SOX11, and Ki67 70%. Vulvar NHL typically has a good prognosis. In fact, NHLs tend to respond well to radio‐chemotherapy, making surgery a less preferred treatment option for vulvar lymphoma. For early‐stage I and II diseases, radiotherapy alone is effective. In contrast, the standard treatment for advanced stages III and IV involves 46 cycles of R‐CHOP chemotherapy (which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), sometimes followed by consolidating radiotherapy. Recent studies have highlighted the significance of the cell type causing DLBCL, with ABC and GCB DLBCLs showing varying responses to standard treatments like rituximab and CHOP chemotherapy. Patients with GCB‐DLBCL usually respond well to R‐CHOP, while those with ABC‐DLBCL may not [16, 17, 18, 19]. Hence it is important to distinguish between these two types because of their difference in clinical implications, prognosis, and differences in the choice of treatment. In comparison to nodal NHL, genital lymphomas seem to be less aggressive and show a very low incidence of recurrence. The prognosis of the genital lymphomas appears to be very good with a 5‐year survival rate occurring between 80% and 90% [20, 21, 22]. Author Contributions M. Singh: conceptualization, investigation, methodology, supervision, writing – review and editing. S. Ngakhusi: conceptualization, resources, writing – original draft, writing – review and editing. A. Shrestha: conceptualization, writing – original draft, writing – review and editing. P. Subedi: conceptualization, resources, writing – original draft, writing – review and editing. K. Khadka: writing – review and editing. H. P. Dhakal: writing – review and editing. Consent Written informed consent was obtained from the patient before the submission of the report. The patient understands that his name and initials won't be mentioned. Conflicts of Interest The authors declare no conflicts of interest. Funding: The authors received no specific funding for this work. Data Availability Statement The data supporting the findings in this case report is available within the article and its supplementary materials. References Associated Data Data Availability Statement The data supporting the findings in this case report is available within the article and its supplementary materials.